Mark Sabag sold $6.1M of TEVA
See "Remarks" at TEVA PHARMACEUTICAL INDUSTRIES LTD. 337,915 shares at an average of $18.04, traded May 8, 2025, filed May 12, 2025.
Score components
- +15RoleOfficer
- +25Trade size$6.1M at market
- +20Share of holdings soldSold 69% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-069132, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2025 | SOpen-market sale Ordinary Shares | -337,915 | $18.04 | $6.1M | 150,996 | May 12, 2025 |
Related signals
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $14M 367,600 shares | -100% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $285k 7,342 shares | -46% | |
| 39Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eliyahu Sharon Kalif EVP, Chief Financial Officer | $952k 55,775 shares | -12% | |
| 28Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Matthew Shields EVP, Global Operations | $106k 6,206 shares | -38% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $1.1M 70,961 shares | -59% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $2.2M 140,372 shares | -419% | |
| 5Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Christine Fox EVP, Head of U.S. Commercial | $98k 6,181 shares | -10% | |
| 21Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard D Francis President and CEO | $376k 23,773 shares | -8% | |
| 30Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eric A Hughes See "Remarks" | $367k 23,251 shares | -100% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $999k 62,250 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.